The Daily This Drug Could End H.I.V. Why Hasn’t It?
Jun 5, 2019
Dr. Robert Grant, a seasoned HIV researcher who developed PrEP, and Donald G. McNeil Jr., a veteran health reporter, discuss the potential of a groundbreaking drug to end the HIV epidemic. They explore the promising results of Truvada, yet highlight challenges such as its high cost and access issues. The conversation reveals the complexities surrounding pharmaceutical practices, including Gilead's initiatives for broader access, and the critical role of journalism in advocating for equitable treatment. It's a candid look at the intersection of science, profit, and public health.
AI Snips
Chapters
Transcript
Episode notes
Dr. Grant's Dedication
- Dr. Robert Grant, upon graduating, expressed his desire to pursue HIV research.
- Despite being discouraged, he persisted, driven by the hope of witnessing the end of the epidemic.
Focus on PrEP
- Dr. Grant focused on HIV prevention, specifically pre-exposure prophylaxis (PrEP).
- He believed Truvada, the chosen drug, would be affordable due to expiring patents.
Truvada's Price Hinders Adoption
- Truvada's high price and lack of advertising hindered widespread adoption.
- Gilead, the manufacturer, offered no explanation for their marketing strategy.